Insights into Pancreatic Cancer Etiology from Pathway Analysis of Genome-Wide Association Study Data

Peng Wei¹, Hongwei Tang²*, Donghui Li²*

¹Division of Biostatistics and Human Genetics Center, School of Public Health, University of Texas Health Science Center, Houston, Texas, United States of America,
²Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Abstract

Background: Pancreatic cancer is the fourth leading cause of cancer death in the U.S. and the etiology of this highly lethal disease has not been well defined. To identify genetic susceptibility factors for pancreatic cancer, we conducted pathway analysis of genome-wide association study (GWAS) data in 3,141 pancreatic cancer patients and 3,367 controls with European ancestry.

Methods: Using the gene set ridge regression in association studies (GRASS) method, we analyzed 197 pathways identified from the Kyoto Encyclopedia of Genes and Genomes database. We used the logistic kernel machine (LKM) test to identify major contributing genes to each pathway. We conducted functional enrichment analysis of the most significant genes (P<0.01) using the Database for Annotation, Visualization, and Integrated Discovery (DAVID).

Results: Two pathways were significantly associated with risk of pancreatic cancer after adjusting for multiple comparisons (P<0.00025) and in replication testing: neuroactive ligand-receptor interaction, (Ps<0.00002), and the olfactory transduction pathway (P=0.0001). LKM test identified four genes that were significantly associated with risk of pancreatic cancer after Bonferroni correction (P<1×10⁻⁵): ABO, HNF1A, OR13C4, and SHH. Functional enrichment analysis using DAVID consistently found the G protein-coupled receptor signaling pathway (including both neuroactive ligand-receptor interaction and olfactory transduction pathways) to be the most significant pathway for pancreatic cancer risk in this study population.

Conclusion: These novel findings provide new perspectives on genetic susceptibility to and molecular mechanisms of pancreatic cancer.

Introduction

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, accounting for more than 37,660 deaths per year [1]. Because no effective screening test exists for pancreatic cancer, it is important to identify genetic factors that contribute to the development of this cancer. Recent genome-wide association studies (GWAS) and post-GWAS analyses have identified chromosome regions containing the ABO, NR5A2, and CLPTM1L-TERT genes [2,3], as well as the HNF1A gene [4], as susceptibility loci for pancreatic cancer. However, single-marker association tests have limited power to identify genes that are genuinely associated with disease status but may not reach a stringent genome-wide significance threshold in GWAS. Thus, many important disease genes may still remain unidentified with this approach. Furthermore, cancer development typically involves dysfunction of multiple functionally related genes acting concordantly in a network or pathways [5]. Thus, pathway analysis of GWAS data, which jointly considers multiple variants in interacting genes and multiple genes in a biological pathway, as a complementary approach to single-marker association tests [6], may have the potential to reveal the polygenic basis of disease susceptibility. Pathway-based GWAS analyses have provided novel insights into the etiology of cancers, such as colon cancer [7], lung cancer [8], and melanoma [9], and other complex diseases, including schizophrenia [10], bipolar disorder [11], and rheumatoid arthritis [12]. A recent study analyzed the GWAS data focusing on 23 selected pathways or groups of genes and identified the pancreas development pathway genes as susceptibility factors for pancreatic cancer [13]. While this data supports the candidate pathway analysis as a useful approach in genetic association study, it is limited by the number of pathways/genes examined, suggesting that a more comprehensive agnostic analysis of all known pathways may have the potential to uncover novel genes that were previously not considered in pancreatic cancer.

Gene set ridge regression in association studies (GRASS) is one of the newly developed pathway-based approaches [7].
GRASS, principal components analysis (PCA) is used to capture the genetic variation within a gene to reduce the dimensionality of the single-nucleotide polymorphism (SNP) data and regularized logistic regression is performed to assess the association of pathways with disease. In this study, we first used GRASS on GWAS data to assess the association of pathways with pancreatic cancer. Then, we applied the logistic kernel machine (LKM) method to screen the major contributing genes to each pathway [14]. Finally, we conducted functional enrichment analysis of the most significant genes using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) method [15,16]. In this study, the first comprehensive analysis of GWAS data in pancreatic cancer using an agnostic approach, we have identified novel pathways and genes that are significantly associated with the disease risk. These findings may open new avenues of research on the molecular mechanism and etiology of pancreatic cancer.

**Methods**

**Study Population and Data Source**

The study population included a total of 7,019 individuals: 1,871 cases and 2,026 from PanScan1 including 12 nested case-control studies and one hospital-based case control study and 1,528 cases and 1,594 controls from PanScan2 including 6 case-control studies on pancreatic cancer [2,3]. Cases were defined as primary adenocarcinoma of the exocrine pancreas. Controls, which were free of pancreatic cancer at the time of recruitment, were matched to cases according to birth year, sex, and self-reported race/ethnicity. GWAS had been performed at the National Cancer Institute’s Core Genotyping Facility using the HumanHap550, HumanHap550-Duo, and Human 610-Quad arrays (all from Illumina, San Diego, CA) [2,3]. The original GWAS data were downloaded from the Database of Genotypes and Phenotypes (dbGaP) [17]. On the basis of ancestry (i.e., 0.75–1 similarity to CEU) were selected from the International HapMap Project genotype data (phase 3 release #3, NCBI build 36, dbSNP b126, 2010-05-28) for three populations (CEU, JPT/CHB, and YRI) [18] and minor allele frequency (MAF) >5%, we selected 10,155 SNPs with $r^2<0.004$ to use in population structure analysis [19]. A total of 6,508 individuals (3,141 cases and 3,367 controls) with European ancestry (i.e., 0.75–1 similarity to CEU) were selected from the starting study population of 7,019 individuals in the current pathway analysis.

**Quality Control**

The original GWAS data passed quality control procedures before posted on dbGaP. We pruned the genotype data by further excluding 13,822 SNPs with call rate <98%, 45,653 SNPs with MAF <5%, and 38,857 SNPs deviating from Hardy–Weinberg equilibrium ($P<0.001$), as well as SNPs in the gene desert regions, resulting in 82,981 SNPs in the final analysis from a starting number of 468,111 SNPs.

In order to evaluate the impact of population structure, we made the quantile-quantile (Q-Q) plot and calculated the inflation factor ($\lambda$) in individuals with European ancestry only. The inflation factor was calculated according to method by de Bakker et al. [20], adjusted for a sample size of 1,000 cases and 1,000 controls using the formula:

$$\lambda_{\text{corrected}} = 1 + (\lambda_{\text{observed}} - 1) \times \frac{1}{n_{\text{case}}} + \frac{1}{n_{\text{control}}}/\left(\frac{1}{1000} + \frac{1}{1000}\right)$$

Where, $n_{\text{case}}$ and $n_{\text{control}}$ are actual number used to calculate $\lambda_{\text{observed}}$. $1,000$ is the sample size to be corrected. Q-Q plot shows little inflation of test statistics compared with expected distribution ($\lambda=1.03$), excluding the possibility of potential population structure between cases and controls.

**Pathways and Genes**

A total of 214 human biological pathways are listed in Kyoto Encyclopedia of Genes and Genomes (KEGG) [21]. After excluding pathways with $<10$ or $>500$ genes, we analyzed 197 pathways using the GRASS approach [22]. We identified 19,058 Reference Sequence (RefSeq) genes in the GWAS data from the human genome 18 (hg18) database using the University of

### Table 1. Pathways significantly associated with pancreatic cancer risk.

| KEGG code | Pathway description | No. of genes | No. of SNPs/No. of eigenSNPs a | P value b | Major contributing genes a |
|-----------|---------------------|--------------|-------------------------------|-----------|----------------------------|
| hsa04080  | Neuroactive ligand-receptor interaction | 263          | 6116/1374                     | 0.00002   | CCKBR CHRM5 EDNRA LPAR1 NMUR1 P2RX4 SSTR3 F2RL3 OPRK1 GZMA S1PR2 SSTR2 CHRN3 SCTR THRB CALCRL D4RD4 VIP1 |
| hsa04664  | Fc epsilon RI signaling pathway | 77           | 1714/405                      | 0.00012   | RAF1 AKT3 RAC2 NRAS MAPIK1 PL2G2A FCER1G HRAS |
| hsa04730  | Long-term depression | 68           | 2649/540                      | 0.00006   | RAF1 ITPR2 NRAS MAPIK1 GN5 GCY1A2 PL2G2A HRAS |
| hsa04950  | Maturity onset diabetes of the young | 24           | 299/91                        | 0.00006   | HNF1A HNF4G NRAS2 PDX1 HNF1B NEUROG3 |
| hsa04270  | Vascular smooth muscle contraction | 113          | 3791/806                      | 0.00024   | ITPR2 RAF1 EDNRA ADCY9 KCNMA1 KCNB2 GCY1A2 GN5 PL2G2A CALCR MAPK1 PL2G2S ADCY3 MYLK3 |
| hsa04740  | Olfactory transduction | 353          | 4084/1122                     | 0.0001    | OR13C4 OR13C3 OR1L4 OR1L6 ORG1 ORG2 ORG2 OR1L1 OR1L3 OR1LC8 OR1LC5 ORM11 ORB88 ORB1 ORB1 ORP1 OR32C3 OR9G4 ORH1 OR14 OR12 OR13C9 OR12 OR18 OR5M10 OR1C1 OR15G1 OR8B OR4G4 OR4A10 OR52W1 OR13A1 OR10H4 OR10C1 OR15M1 OR13F1 OR52B2 OR5M1 OR5184 OR51A2 OR14A16 OR15F2 OR10G3 OR5L1 OR5A4 OR51G2 |

Note: All 6 pathways were significant after Bonferroni correction ($P=2.30\times10^{-5}$).

aNo. of SNPs refers to the actual number of SNPs. No. of eigenSNPs refers to the number of uncorrelated linear combinations of SNPs used in GRASS analysis.

bP value obtained from GRASS analysis based on 50,000 permutations.

Genes associated with pancreatic cancer with $P<0.001$, identified using the logistic kernel machine (LKM) method.

[102x303]3, NCBI build 36, dbSNP b126, 2010-05-28) for three populations (CEU, JPT/CHB, and YRI) [18] and minor allele frequency (MAF) >5%, we selected 10,155 SNPs with $r^2<0.004$ to use in population structure analysis [19]. A total of 6,508 individuals (3,141 cases and 3,367 controls) with European ancestry (i.e., 0.75–1 similarity to CEU) were selected from the starting study population of 7,019 individuals in the current pathway analysis.

Quality Control

The original GWAS data passed quality control procedures before posted on dbGaP. We pruned the genotype data by further excluding 13,822 SNPs with call rate <98%, 45,653 SNPs with MAF <5%, and 38,857 SNPs deviating from Hardy–Weinberg equilibrium ($P<0.001$), as well as SNPs in the gene desert regions, resulting in 82,981 SNPs in the final analysis from a starting number of 468,111 SNPs.

In order to evaluate the impact of population structure, we made the quantile-quantile (Q-Q) plot and calculated the inflation factor ($\lambda$) in individuals with European ancestry only. The inflation factor was calculated according to method by de Bakker et al. [20], adjusted for a sample size of 1,000 cases and 1,000 controls using the formula:

$$\lambda_{\text{corrected}} = 1 + (\lambda_{\text{observed}} - 1) \times \frac{1}{n_{\text{case}}} + \frac{1}{n_{\text{control}}}/\left(\frac{1}{1000} + \frac{1}{1000}\right)$$

Where, $n_{\text{case}}$ and $n_{\text{control}}$ are actual number used to calculate $\lambda_{\text{observed}}$. $1,000$ is the sample size to be corrected. Q-Q plot shows little inflation of test statistics compared with expected distribution ($\lambda=1.03$), excluding the possibility of potential population structure between cases and controls.

Pathways and Genes

A total of 214 human biological pathways are listed in Kyoto Encyclopedia of Genes and Genomes (KEGG) [21]. After excluding pathways with $<10$ or $>500$ genes, we analyzed 197 pathways using the GRASS approach [22]. We identified 19,058 Reference Sequence (RefSeq) genes in the GWAS data from the human genome 18 (hg18) database using the University of
California Santa Cruz (UCSC) Table Browser data retrieval tool [23]. We tested 5,127 genes in the 197 pathways for association with pancreatic cancer. For each gene region, we included SNPs within 20 kb upstream or downstream of the gene in this study.

Statistical Methods

We used GRASS to test the association of each pathway with pancreatic cancer. Genotype data were coded in an additive model using PLINK version 1.07 [24] with 0 for homozygote common allele, 1 for heterozygote, and 2 for homozygote mutant allele. The GRASS tests the null hypothesis that none of the SNPs in a given pathway was associated with the disease [6]. To avoid undue influence of varying gene and pathway sizes, the GRASS uses normalized gene-level statistics and sample (subject) permutations. The details of GRASS have been previously described [7]. Briefly, the method consists of three steps. First, PCA is used to summarize SNPs in each gene as uncorrelated (orthogonal) linear combinations of the original SNPs, called eigenSNPs, accounting for ≥95% of the genetic variation. The number of resulting eigenSNPs is usually much smaller than that of the original genotyped SNPs and serves as predictors in the regularized logistic regression model. A penalized likelihood function is used to estimate the regression coefficients of the eigenSNPs. Second, a standardized gene-level statistic is calculated according to the regression coefficients of the eigenSNPs. The statistic, analogous to z-statistic, is defined as

| Pathway code | Pathway description | Combined | Panscan1 | Panscan2 | Stouffer’s meta-p | Random1 | Random2 | Stouffer’s meta-p |
|--------------|---------------------|----------|----------|----------|-------------------|---------|---------|-------------------|
| hsa04080     | Neuroactive ligand-receptor interaction | 0.00002   | 0.00006  | 0.002    | <1.0 × 10⁻⁵     | 0.0256  | 0.279   | 0.0365            |
| hsa04664     | Fc epsilon RI signaling pathway         | 0.00012   | 0.11     | 0.18     | 0.065            | 0.0624  | 0.0076  | 0.0025            |
| hsa04730     | Long-term depression                    | 0.000006  | 0.1232   | 0.14     | 0.057            | 0.5422  | 0.0418  | 0.1254            |
| hsa04950     | Maturity onset diabetes of the young    | 0.000006  | 0.000006 | 0.91     | 0.038            | 0.0856  | 0.0676  | 0.0215            |
| hsa04270     | Vascular smooth muscle contraction      | 0.000024  | 0.10     | 0.10     | 0.035            | 0.357   | 0.0352  | 0.0620            |
| hsa04740     | Olfactory transduction                  | 0.0001    | 0.0015   | 0.002    | 1.0 × 10⁻⁵      | 0.0036  | 0.0816  | 0.0020            |

Figure 1. Genes significantly associated with pancreatic cancer (P<0.01 in LKM) in all 197 pathways analyzed in this study. doi:10.1371/journal.pone.0046887.g001
we adopted a two-stage permutation test procedure, similar to that used in EIGENSTRAT [26]. P values from the KLM analysis were estimated using \[ T^g_b = \frac{1}{B} \sum_{i=1}^B \left( \hat{\beta}_g - \hat{\mu}_g \right)^2 \], where \( \hat{\beta}_g \) is the square root of summation of squared regression coefficient for each eigenSNP estimated under the optimal tuning parameter \( \lambda \); \( \hat{\mu}_g \) and \( \sigma_g \), estimated from permutations, are mean and standard deviation of \( \left( \hat{\beta}_g \right) \) under the null hypothesis that gene \( g \) is not associated with the disease. Thus, each gene, regardless of its size, contributes equally to the gene set association statistic, as described below. The third step involves calculating gene set (pathway) association statistic \( T_3 \) and p value. \( T_3 \) is the square root of summation of squared standardized gene-level statistics; \( P \) value is estimated using \[ \{ T^g_3(\lambda) / B \}_{\lambda=1,2,\ldots, B} \], where \( T^g_3(\lambda) \) is computed from the permutated data and \( B \) is the number of permutations. Because of the large number of genes and pathways analyzed, we applied the Bonferroni correction to adjust for multiple comparisons. The significance threshold was \( P < 0.00025 \) (0.05/197). Due to the intensive computation entailed by GRASS, we adopted a two-stage permutation test procedure, similar to that implemented in PLINK [24]: we first conducted 5,000 permutations to each gene set in this study, and for those gene sets with p-value less than 0.00025, we increased the number of permutations to 50,000.

We applied the LKM test to assess the association of each gene with pancreatic cancer as previously described [14]. Briefly, this method comprises two steps: forming SNP sets for each gene and testing the association of SNP sets with disease status. The gene database, gene region definition, and genotype coding used here were the same as those in GRASS. The LKM model integrates a regular logistic model with a semi-definite kernel function (a linear kernel was used here) that is specifically designed for genetic data. The variance-components score test of Zhang and Lin [25] was used to test gene–disease association. In this analysis, we tested the associations of 5,127 genes (in the 197 pathways) with pancreatic cancer after adjusting for age (in 10-year groups), sex, study (categorical), and five principal components (quantitative) capturing population structure obtained from a PCA analysis using EIGENSTRAT [26]. P values from the KLM analysis were adjusted for multiple comparisons using the Bonferroni correction. The significance threshold was \( P < 0.0001 \) in LKM.

Finally, as a complementary approach to the GRASS pathway analysis, we investigated the functional enrichment of the most significant genes in gene-based association tests (\( P < 0.01 \) in LKM) using the web-accessible bioinformatics tool DAVID [15,16]. The DAVID consists of an integrated biological knowledgebase and analytic tools aimed at systematically extracting biological meaning and over-represented biological functions from large gene or protein lists based on the hypergeometric (Fisher’s exact)

---

Table 3. Genes associated with pancreatic cancer risk at \( P \) values <0.0001 in LKM analysis.

| Gene | \( P \) value* | Full name | No. of SNPs/No. of eigenSNPs** | KEGG code |
|------|----------------|-----------|-------------------------------|-----------|
| ABO  | 1.56 \times 10^{-6} | ABO blood group (transferase A, alpha 1-3-N-acetylglucosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) | 23/5 | hsa00601 |
| HNF1A | 1.69 \times 10^{-6} | HNF1 homeobox A | 16/4 | hsa04950 |
| OR13C4 | 6.63 \times 10^{-6} | olfactory receptor, family 13, subfamily C, member 4 | 13/4 | hsa04740 |
| SHH  | 8.18 \times 10^{-6} | sonic hedgehog | 14/4 | hsa05217 hsa05200 hsa04340 |
| OR13C3 | 1.03 \times 10^{-5} | olfactory receptor, family 13, subfamily C, member 3 | 14/4 | hsa04740 |
| HNF4G | 2.62 \times 10^{-5} | hepatocyte nuclear factor 4, gamma | 14/5 | hsa04950 |
| MYC  | 2.73 \times 10^{-5} | v-myc myelocytomatosis viral oncogene homolog (avian) | 4/1 | hsa05222 hsa05221 hsa05220 |
| NRS2A | 6.76 \times 10^{-5} | nuclear receptor subfamily 5, group A, member 2 | 55/12 | hsa04950 |
| ADPGK | 7.92 \times 10^{-5} | ADP-dependent glucokinase | 8/3 | hsa00010 |
| ABL1 | 8.95 \times 10^{-5} | c-abl oncogene 1, non-receptor tyrosine kinase | 30/7 | hsa05416 hsa05220 hsa05200 |

Note: The first four genes were significant after Bonferroni correction (\( P < 9.75 \times 10^{-6} \)).

*\( P \) value obtained from LKM analysis.

**No. of SNPs refers to the actual number of SNPs; “No. of eigenSNPs” refer to the number of uncorrelated linear combinations of SNPs used in GRASS analysis.

doi:10.1371/journal.pone.0046887.t003
test. We used the KEGG, GO and InterPro [27] databases to define the gene sets. In addition, DAVID groups functionally similar gene sets into clusters to reduce the redundant nature of gene functional annotation systems, e.g., the hierarchically organized GO.

As a replication effort, we analyzed the data from PanScan1 (1,796 cases and 1,880 controls) and PanScan2 (1,345 cases and 1,487 controls) separately. We also randomly split the entire dataset into two groups and conducted separate analysis in each group. We performed meta-analysis of the $P$ values from individual cohort/group using the Stouffer’s z-score method, which has been demonstrated to be efficient in meta-analysis of GWAS [28]. The test statistic for combining $p$-values from two individual cohorts for a given pathway is computed as $z = \Phi^{-1}(1 - p_1) + \Phi^{-1}(1 - p_2) / \sqrt{2}$, where $\Phi^{-1}$ is inverse of the standard normal cumulative function. The overall meta-analysis $P$ value is calculated as $1 - \Phi(z)$. Finally, we applied the GRASS method to test the two largest significant pathways (as detailed in Results) using the Wellcome Trust Case Control Consortium (WTCCC) GWAS data [29] to empirically evaluate the impact of pathway size and demonstrate the specificity of our results.

Results

Pathways Associated with Pancreatic Cancer

We analyzed 197 pathways with 5,127 genes using the GRASS approach and found that six pathways were significantly associated with pancreatic cancer after the Bonferroni correction ($P < 2.5 \times 10^{-4}$) (Table 1). Three pathways were significant at $P$ values $<0.0001$: neuroactive ligand-receptor interaction, long-term depression, and maturity onset diabetes of the young (MODY) pathways. Three pathways had a less significant $P$ value of $<0.0001$ but $<0.00025$: the olfactory transduction, Fc epsilon RI signaling, and the vascular smooth muscle contraction pathways. In addition to the above six pathways, the glycerophospholipid metabolism, pancreatic secretion and vascular endothel...
functional growth factor (VEGF) signaling pathways were associated with pancreatic cancer at \( P = 0.0004 \) (Table S1, available online).

**Pathway Replication Results**

Two of the six significant pathways, i.e., the olfactory transduction pathway and the neuroactive ligand-receptor interaction pathway showed consistent small \( P \) values across the PanScan1 and PanScan2 cohorts, though not both \( P \) values were significant after multiple testing corrections likely due to much smaller sample size in each individual cohort and the resulting lower statistical power (Table 2). The meta-analysis \( P \) values for these two pathways (1 × 10^{-5} and 4 × 10^{-5}, respectively) were significant after the Bonferroni correction. The MODY pathway remained significant in PanScan1 (\( P = 0.00006 \)) but not in PanScan2 (\( P = 0.91 \)), and the meta-analysis \( P \) value was 0.0589. All three remaining significant pathways in the combined GRASS analysis had \( P \) values > 0.1 in the PanScan1 and PanScan2 cohort (Table 2). When we randomly split the dataset into two groups, all six pathways had a \( P \) value < 0.05 in one of the two groups but not in both; and none of the meta-analysis \( P \) values was significant after adjusting for multiple comparisons (Table S2). To investigate if the significance of the olfactory transduction pathway (353 genes and 1,122 eigenSNPs) and the neuroactive ligand receptor interaction pathway (263 genes and 1,374 eigenSNPs) was simply due to their large size, we tested these pathways by applying the GRASS to the WTCCC GWAS data and obtained a \( P \) value of 0.5652 and 0.2332 for bipolar disorder and 0.246 and 0.0062 for Crohn’s disease, respectively, (each disease had 2,000 cases and 3,000 controls). These results, along with the consistent small \( P \) values across PanScan1 and PanScan2, indicate that the significant \( P \) value of these two pathways in the GRASS analysis is unlikely due to the pathway size. In addition, to investigate if the pathway results were mainly driven by GWAS top hits reported in PanScan1 and PanScan2, we removed the gene NR5A2 gene, suggesting that our pathway analysis unraveled signals independent from...
those by single-SNP analysis. Note that other GWAS top hits such as ABO and TERT1 were not included in any of the 197 pathways.

**Major Contributing Genes to Pathways**

Applying the LKM method, we identified 365 genes with nominal significance \((P<0.05)\) and 118 genes with \(P<0.01\) for the 197 pathways (Table S3, available online). The major contributing genes to each of the six significant pathways identified by GRASS are listed in Table 1. The major genes contributing to the 197 pathways and to the six significant pathways are presented in Figure 1 and 2, respectively. After we adjusted for multiple comparisons, four genes remained significant \((P<9.75 \times 10^{-6})\); the ABO, HNF1A, OR13C4, and SHH genes (Table 3). In addition to these four genes, ABL1, MYC, HNF4G, and NR5A2 (a GWAS top hit) and ADPGK had \(P\) values \(<0.0001\).

**Functional Enrichment Analysis of Significant Genes**

Finally, we conducted functional enrichment analysis, using DAVID, on the set of 118 genes with \(P<0.01\) from LKM analysis. Forty-four clusters were identified on the basis of the KEGG, GO and InterPro categories. The clusters of genes with \(P<0.01\) from DAVID are listed in Table 4 (See Table S4 for detailed list of genes in each cluster). The superfamily of rhodopsin-like G protein-coupled receptors (GPCRs), perception of smell and olfactory transduction was the most significant group of genes on the basis of the InterPro \((P=1.61 \times 10^{-18})\), GO \((P=1.30 \times 10^{-7})\) and KEGG \((2.30 \times 10^{-3})\) databases, respectively, echoing our findings from GRASS. Genes maintaining the homeostasis process were also over-represented in pancreatic cancer (Table 4). The biologic relationship map for the top 81 genes \((P<0.05\) in LKM) of the six significant pathways is shown in Figure 3, which was created with Ingenuity Pathway and Analysis software [30].

**Discussion**

In this GWAS pathway analysis, we identified two novel pathways, i.e. the neuroactive ligand receptor interaction and olfactory transduction pathways that are significantly associated with pancreatic cancer risk after adjusting for multiple comparisons and in replication testing. These findings were also supported by functional enrichment analysis. We also identified four genes that are significantly associated with pancreatic cancer risk, including three previously implicated genes ABO, HNF1A, and SHH [2–4] as well as a novel gene OR13C4. These findings provide new provocative insights into the polygenic basis of pancreatic cancer susceptibility and etiology.

The GPCR protein superfamily of transmembrane receptors accounts for \(\sim 4\%\) of the whole human genome and \(>50\%\) of modern therapeutic targets [31]. Genes of the neuroactive ligand-receptor interaction and olfactory transduction pathways are major components of the GPCRs (Table S4). The neuroactive ligand-receptor interaction pathway remained significant after adjusting for multiple testing in PanScan1 \((P=0.0006)\) but not in PanScan2 \((P=0.002)\). However, the \(P\) value from meta-analysis was highly significant \((P<1 \times 10^{-5})\). The contributing genes to this pathway, e.g. CCKBR, CHRM5, EDNRA, LPAR1, SSTR2/3, and SCTR, have diverse functions in regulating the endocrine and exocrine functions of the pancreas, which are highly relevant to pancreatic cancer [32,33,34,35].

Humans have >700 olfactory receptor (OR) genes (of which \(\geq 50\%\) are functional) [36]. Genetic variants of the OR genes and dysfunctions of OR signaling have previously been associated with schizophrenia [37], fetal hemoglobin in sickle-cell anemia [38], and proliferation of prostate cancer cells [39]. Although the links between olfactory transduction and pancreatic cancer remain to be elucidated, a previous sequencing analysis of human pancreatic tumors did find many somatic mutations of the OR genes, including seven genes identified in the current analysis: OR13C3, OR13C5, OR10P1, OR172, OR4A16, OR5I2, and OR5D13 [40]. Expression of at least two OR genes has been reported in human pancreas tissues [41]. The top two contributing genes to the olfactory transduction pathway, OR13C4 and OR13C5, ranked as the third and fifth most significant genes among the 5,127 genes analyzed in this study. In the replication study, the olfactory transduction pathway remained as one of the top pathways with consistent small \(P\) values in PanScan1 and PanScan2 cohort with a significant meta-analysis \(P\) value after adjusting for multiple testing. On the other hand, we did not find any association of this pathway with bipolar or Crohn’s disease in the WTCCC GWAS data analysis. All these data suggest that the association of olfactory transduction pathway and pancreatic cancer are unlikely to be due to chance. Further replication of this association in other dataset and functional studies of the biological and molecular links between olfactory transduction signaling and pancreatic cancer are warranted. GPCRs are the first gate through which outside signals are transmitted into the cell. High activity of GPCRs may contribute to transduction of outside detrimental signals, such as insulin, glucose, or carcinogens, into a cell and induce a cascade of responses related to carcinogenesis.

In addition to these two pathways, four additional pathways also passed the Bonferroni correction for multiple comparisons, i.e. the MODY, Fc epsilon RI, long-term depression and vascular smooth muscle contraction pathways. However, the MODY pathway was highly significant in PanScan1 but was not significant in PanScan2. The diminished or weaker gene-risk association in PanScan2 has previously been observed for other genes [3,4]. This difference may be related to the fact that PanScan1 was pooled from 12 cohort studies and one case control study while PanScan2 was drawn from eight case control studies. Because of the rapid fatality of pancreatic cancer, case control study may subject to a survival bias if the testing genes are associated with survival. Although meta-analysis did not show a significant \(P\) value, this pathway has been identified as the most significant pathway in association with pancreatic cancer in a separate analysis of the PanScan data using two different statistical methods [13]. The MODY genes are an important part of the transcriptional network that regulates pancreas development and differentiation in early life and maintains pancreatic homeostasis in adulthood [42,43,44]. Three MODY genes (HNF1A, HNF4G, and NR5A2) were among the top 10 genes with \(P\) values \(<0.0001\) in LKM analysis. Notably, another two of the top 10 genes, SHH and MYC, are also known to play an essential role in pancreas development [45]. Genes involved in organ development and differentiation may contribute to the ability of tumor cells to proliferate and survive, as well as alter cell plasticity, thus reprogramming cells to a state that can give rise to a tumor. MODY genes may also contribute to pancreatic cancer by modifying the risk of diabetes [46] and obesity [47,48], or by regulating epithelial cell growth and differentiation, lipid metabolism [49], protein fucosylation [50], and inflammation [51].

Fc epsilon RI is a high affinity receptor for IgE, and mast cell activation mediated by Fc epsilon RI is a key event in the allergic inflammatory response. Increasing evidence indicates that inflammation around tumor, including infiltration by mast cells, facilities tumor growth and angiogenesis in pancreatic cancer [52,53]. However, this pathway along with the long-term depression and vascular smooth muscle contraction pathways did not have
consistent results in the replication studies. Thus, these data need to be treated with caution.

Compared to findings from the previously reported candidate pathway/gene analysis [13], our findings on pathways that were included in both studies were quite consistent, i.e. a positive finding on the pancreas development (aka MODY) pathway/genes and the negative findings on the DNA repair, apoptosis, insulin signaling, wnt, notch and hedgehog pathways/genes.

This is by far the largest study in pancreatic cancer with the most comprehensive analysis of all biological pathways identified from KEGG using an agnostic approach. Using PCA in GRASS greatly reduced the dimensionality of the GWAS data and increased the probability of singling out useful information. Using the LKM method overcame the influences of positive and negative effects of SNPs and enabled us to identify new genes in addition to replicating the gene regions discovered by previous marginal-association studies [34]. By performing the GRASS analysis in two independent cohorts, we have shown consistent findings on some of the significant pathways. Further replication of these findings in future additional pancreatic cancer GWAS data is warranted. Overall, the pathway analysis approach with intensive control for false positive findings has a great potential to uncover gene traits that are associated with disease without a priori. Correct use of this tool may open up new avenues of research on the molecular mechanisms of pancreatic cancer and potential targets for the prevention and treatment of this disease.

References

1. American Cancer Society (2012) Cancer Facts and Figures 2012.
2. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Peterson GM, et al. (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 41: 986–990.
3. Peterson GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, et al. (2010) A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13p22.1, 1q12.1 and 5p15.33. Nat Genet 42: 224–228.
4. Pierce BL, Ahsan H (2011) Genome-wide “pleiotropy scan” identifies HNF1A region as a novel pancreatic cancer susceptibility locus. Cancer Res 71: 4532–4538.
5. Schadt EE (2009) Molecular networks as sensors and drivers of common human diseases. Nature 461: 210–223.
6. Wang K, Li M, Hakonarson H (2010) Analysing biological pathways in genomewide association studies. Nat Rev Genet 11: 485–494.
7. Chen LS, Hutter CM, Potter JD, Liu Y, Prentice RL, et al. (2010) Insights into Colon Cancer Etiology via a Regularized Approach to Gene Set Analysis of GWAS Data. Am J Hum Genet 86: 224–228.
8. Fehringer G, Liu G, Briolias L, Brennan P, Amos CI, et al. (2012) Comparison of pathway analysis approaches using lung cancer GWAS data sets. PLoS One 7: e31016.
9. School N, Iles MM, Bishop DT, Newton-Bishop JA, Barrett JH (2011) Pathway-based analysis of a melanoma genomewide association study: analysis of genes related to tumour-immunosuppression. PLoS One 6: e29451.
10. Jia P, Wang L, Fanous AH, Chen X, Kendler KS, et al. (2012) A bias-reducing pathway enrichment analysis of genome-wide association data confirmed association of the MHC region with schizophrenia. J Med Genet 49: 96–103.
11. Holmans P, Green EK, Pahwa JS, Ferreira MA, Purcell SM, et al. (2009) Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder. Am J Hum Genet 85: 13–24.
12. Luo L, Peng G, Zhu Y, Dong H, Amos CI, et al. (2010) Genome-wide gene and pathway analysis. Eur J Hum Genet 18: 1045–1053.
13. Lin D, Duell EJ, Yu K, Risch HA, Olson SH, et al. (2012) Pathway Analysis of Genomewide Association Study Data Highlights Pancreatic Development Genes as Susceptibility Factors for Pancreatic Cancer. Carcinogenesis 33: 1384–90.
14. Wu MC, Kraft P, Epstein MP, Taylor DM, Chanoock SJ, et al. (2010) Powerful SNP set analysis for case-control genomewide association studies. Am J Hum Genet 86: 929–942.
15. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1–13.
16. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.
17. NCBI website. Available: https://dbgap.ncbi.nlm.nih.gov/. Accessed 2010 Dec 9.
18. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Steve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851–861.
19. Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multifocus genotype data. Genetics 155: 945–955.
20. de Bakker PI, Ferreira MA, Jia X, Neale BM, Raychaudhuri S, et al. (2008) Practical aspects of imputation-driven meta-analysis of genomewide association studies. Hum Mol Genet 17: R122–128.
21. Kanesha M, Goto S, Furumiruc M, Tanahe M, Hirakawa M (2010) KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 38: D355–360.
22. Wang K, Li M, Bucan M (2007) Pathway-based approaches for analysis of genomewide association studies. Am J Hum Genet 81: 1278–1283.
23. Caroñchik D HA, Furry TS, Roskin KM, Sunet CW, Hausler D, et al. (2004) The UCSC Table Browser data retrieval tool. Nucleic Acids Res 32(Database issue): D493–6.
24. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
25. Zhang D, Liu X (2003) Hypothesis testing in semiparametric additive mixed models. Biostatistics 4: 57–74.
26. Price AL, Patterson NJ, Zlegen RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genomewide association studies. Nat Genet 38: 904–909.
27. EMBL-EBI Website. Available: http://www.ebi.ac.uk/interpro/. Accessed 2012 April 5.
28. Willer C, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26: 2190–2191.
29. WTCCC (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661–678.
30. ENGenuity Website. Available: http://www.ingeniumx.com/. Accessed 2012 April 5.
31. Lappano R, Maggioni M (2011) G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 10: 47–60.
32. Reifeld JF (2004) Clinical endocrinology and metabolism. Cholecystokinin. Best Pract Res Clin Endocrinol Metab 18: 569–586.
33. Anney RJ, Lotfi-Miri M, Olsson CA, Reid SC, Hemphill SA, et al. (2007) Variation in the gene coding for the M5 muscarinic receptor (CHRM5) influences cigarette dose but is not associated with dependence to drugs of addiction: evidence from a prospective population based cohort study of young adults. BMJ Genet 8: 46.
34. Darrah R, McKone E, O’Connor C, Rodgers C, Genatossio A, et al. (2010) EDRNA variants associate with smooth muscle mRNA levels, cell proliferation

Supporting Information

Table S1 List of 197 biological pathways analyzed in this study. (XLS)
Table S2 Results of GRASS analysis in subgroups and in WTCCC GWAS dataset. (XLS)
Table S3 List of 5,127 genes analyzed in this study. (XLS)
Table S4 List of genes in each cluster identified in DAVID analysis. (XLS)

Acknowledgments

We thank all contributors to the PanScan GWAS. We thank Dr. Yuxin Fu for his advice on the population structure analysis and Mr. Jin Yu for his help with the intensive computation using the CLUSTER system at the University of Texas, School of Public Health at Houston.

Author Contributions

Conceived and designed the experiments: DL, PW. Performed the experiments: HT PW. Analyzed the data: HT PW. Contributed reagents/materials/analysis tools: DL, PW. Wrote the paper: PW HT DL. Obtained permission for use of GWAS data in this analysis: DL. Obtained data from KEGG, HapMap and other databases: HT. Developed the R codes for the statistical analysis: PW.
rates, and cystic fibrosis pulmonary disease severity. Physiol Genomics 41: 71–77.

35. Hayes GM, Carrigan PE, Dong M, Reubi JC, Miller LJ (2007) A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma. Gastroenterology 133: 853–861.

36. Niimura Y, Nei M (2003) Evolution of olfactory receptor genes in the human genome. Proc Natl Acad Sci U S A 100: 12235–12240.

37. Turetsky BI, Hahn CG, Bergmann-Winter K, Moberg PJ (2009) Scents and nonsense: olfactory dysfunction in schizophrenia. Schizophr Bull 35: 1117–1131.

38. Solovieff N, Milton JN, Hartley SW, Sherva R, Sebastiani P, et al. (2010) Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 3′ olfactory receptor gene cluster. Blood 115: 1815–1822.

39. Neuhaus EM, Zhang W, Geda L, Deng Y, Noldus J, et al. (2009) Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem 284: 16218–16225.

40. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801–1806.

41. Feldmesser E, Olender T, Khen M, Yanai I, Ophir R, et al. (2006) Widespread ectopic expression of olfactory receptor genes. BMC Genomics 7: 121.

42. Maestro MA, Carrhalda C, Boj SF, Luco RF, Servitja JM, et al. (2007) Distinct roles of HNF1beta, HNF1alpha, and HNF4alpha in regulating pancreas development, beta-cell function and growth. Endocr Dev 12: 33–43.

43. Rukstalis JM, Habener JF (2009) Neurogenin3: a master regulator of pancreatic islet differentiation and regeneration. Islets 1: 177–184.

44. Oliver-Krasinski JM, Kasner MT, Yang J, Crosthwaite MF, Rustgi AK, et al. (2009) The diabetes gene Pbc1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice. J Clin Invest 119: 1888–1898.

45. Morris JP, Wang SC, Hrubek M (2010) KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10: 683–695.

46. Voight BF, Scott LJ, Steinthorsdotir V, Morris AP, Dina C, et al. (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42: 579–589.

47. Gerdin AK, Sixhe VV, Jonsson M, Bjarsell M, Bjorkman M, et al. (2006) Phenotypic screening of hepatocyte nuclear factor (HNF) 4-gamma receptor knockout mice. Biochem Biophys Res Commun 349: 825–832.

48. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, et al. (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42: 957–948.

49. Kashireuan S, Willer CJ, Pelosi GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56–65.

50. Luan G, Esafi A, Huffman JE, Hayward C, Knzevic A, et al. (2010) Genomics meets glycomics—the first GWAS study of human N-Glycome identifies HNF1alpha as a master regulator of plasma protein fucosylation. PLoS Genet 6: e1001256.

51. Delghani A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, et al. (2011) Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 123: 731–738.

52. Esposito I, Minicagli M, Fumel N, Bergmann F, Boggi U, et al. (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57: 630–636.

53. Strouch MJ, Chen EC, Salabat MR, Kranz SB, Gounaris E, et al. (2010) Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res 16: 2257–2265.

54. Goode EL, Chenevix-Trench G, Song H, Rams SJ, Notaridou M, et al. (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 6q24. Nat Genet 42: 874–879.